Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The UK Government has signed an agreement with Pfizer and BioNTech for the supply of 30 million doses of the companies’ mRNA-based Covid-19 vaccine candidate, BNT162.
Neither company divulged financial details of the deal, but the terms were said to be contingent on the delivery timing and the volume of doses.
Based on BioNTech’s mRNA technology, BNT162 sss Pfizer’s expertise in vaccine development and manufacturing. The vaccine candidate is currently undergoing clinical studies.
BioNTech CEO and co-founder Ugur Sahin said: “This agreement is part of our commitment to address the pandemic by creating a global supply. “We are in.